CRDF - Company ID 0001213037
The table below shows Cardiff Oncology, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$12.29M | -$12.79M | -$7.74M | -$8.66M | -$10.25M | -$5.88M |
| Capital expenditure | - | - | $80.00K | $8.00K | $171.00K | $0.00 |
| Investing cash flow | $3.26M | -$14.58M | $4.64M | $7.33M | $18.36M | -$111.70M |
| Dividends paid | - | - | - | - |
Cardiff Oncology, Inc. reported operating cash flow of -$37.92M for fiscal year 2025. That is down 0.6% from -$37.69M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow declined from -$13.20M (FY 2018) to -$37.92M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $105.00K | $3.00K | $107.00K | $0.00 | $0.00 | $1.26M |